Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) will host an investor webcast on May 21, 2026 at 5:30 p.m. ET. The event will highlight updated results from the ongoing Phase 2 trial of silevertinib in frontline EGFR-mutated non-small cell lung cancer.

The webcast is accessible via the Investors & Events section of Black Diamond's website, with a replay available for a limited time.

News Market Reaction – BDTX

+16.28% 6.0x vol

82 alerts

+16.28% Session close to close

+47.4% Peak in 23 hr 19 min

$227.20M Market Cap

6.0x Rel. Volume

In the May 19 session, BDTX gained 16.28%, reflecting a significant positive market reaction. Argus tracked a peak move of +47.4% during that session. Our momentum scanner triggered 82 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 6.0x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +16.3% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +16.3% in the session following this news. A strong positive reaction aligns with the company’s strategy of spotlighting silevertinib data, though past clinical headlines averaged a -9.46% move. Investors have seen frequent NSCLC and GBM updates, alongside an effective $500,000,000 shelf and an at-the-market component up to $150,000,000. Such financing capacity could weigh on sustainability if heavily used, while prior instances show that upbeat data alone has not always led to durable gains.

Key Figures

Webcast date: May 21, 2026 Webcast time: 5:30 p.m. ET Announcement date: May 19, 2026

3 metrics

Webcast date May 21, 2026 Investor webcast on updated Phase 2 silevertinib results

Webcast time 5:30 p.m. ET Scheduled start time for investor webcast

Announcement date May 19, 2026 Press release date for webcast notice

Previous Clinical trial Reports

5 past events · Latest: Apr 21 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 21	ASCO data presentations	Positive	+3.3%	Announced multiple ASCO 2026 presentations of Phase 2 silevertinib data.
Dec 03	Phase 2 NSCLC data	Positive	-22.0%	Reported preliminary Phase 2 silevertinib results in 1L NSCLC and GBM plans.
Dec 02	Clinical webcast notice	Positive	-22.0%	Announced webcast to present Phase 2 silevertinib results and program update.
Sep 23	Recurrent NSCLC data	Positive	-5.5%	Released initial Phase 2 BDTX-1535 data in recurrent EGFRm NSCLC.
Jun 01	GBM clinical data	Positive	-1.1%	Presented Phase 1 BDTX-1535 data in recurrent GBM at ASCO 2024.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial headlines for silevertinib have often been followed by negative price reactions, with 4 of 5 past clinical updates trading down despite positive-sounding data.

Recent Company History

Over the past two years, Black Diamond has steadily advanced silevertinib through Phase 2 in EGFR-mutant NSCLC and GBM, with multiple data updates and ASCO presentations. Clinical news has included robust response rates in frontline and recurrent NSCLC and promising GBM activity, yet same-tag headlines often saw shares fall. Today’s webcast announcement continues that pattern of frequent clinical communication and follows prior Phase 2 NSCLC data disclosures and ASCO-focused updates dated 2024–2026.

Key Terms

phase 2 trial, nsclc, webcast

3 terms

phase 2 trial medical

"updated results from its ongoing Phase 2 trial of silevertinib"

A phase 2 trial is an intermediate-stage clinical study that tests whether a new treatment works and is reasonably safe in a group of patients who have the condition it targets. Think of it as a field test of a prototype product: it checks real-world effectiveness and side effects on a modest number of users to decide whether the treatment should move to larger, definitive testing. Investors watch phase 2 results because positive outcomes can sharply increase the likelihood of regulatory approval and future sales, while failures often halt development.

nsclc medical

"EGFR mutated non-small cell lung cancer on Thursday, May 21, 2026"

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

webcast technical

"will host a webcast for investors to present updated results"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET

CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast for investors to present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer on Thursday, May 21, 2026, at 5:30 p.m. ET.

Webcast information

The webcast can be accessed under “Events and Presentations” on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event for a limited time.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing silevertinib, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts

For Investors:
investors@bdtx.com

For Media:
media@bdtx.com

FAQ

When is the Black Diamond Therapeutics (BDTX) silevertinib Phase 2 results webcast?

The silevertinib Phase 2 results webcast is scheduled for May 21, 2026 at 5:30 p.m. ET. According to Black Diamond Therapeutics, this webcast will present updated data in frontline EGFR-mutated non-small cell lung cancer for investors.

How can investors access the Black Diamond Therapeutics (BDTX) silevertinib Phase 2 webcast?

Investors can access the webcast through the Investors section of the Black Diamond Therapeutics website, under “Events and Presentations.” According to Black Diamond Therapeutics, the link will stream the live event and provide information on the replay.

Will a replay be available for the Black Diamond Therapeutics (BDTX) May 21, 2026 webcast?

Yes, a replay of the May 21, 2026 investor webcast will be available for a limited time. According to Black Diamond Therapeutics, the replay can be accessed via the Events and Presentations section on the company’s investor webpage.

What is the focus of Black Diamond Therapeutics’ silevertinib Phase 2 trial in EGFRm NSCLC?

The Phase 2 trial focuses on silevertinib in frontline patients with EGFR-mutated non-small cell lung cancer. According to Black Diamond Therapeutics, the May 21, 2026 webcast will present updated clinical results from this ongoing study to investors.

What type of company is Black Diamond Therapeutics (Nasdaq: BDTX)?

Black Diamond Therapeutics is described as a clinical-stage oncology company developing MasterKey therapies targeting families of oncogenic mutations. According to Black Diamond Therapeutics, these therapies aim to treat patients with cancer driven by specific genetic alterations.